醫思健康(02138.HK)公佈年度業績:營收達38.75億港元創歷史新高,純利超1億港元
格隆匯6月23日丨醫思健康(02138.HK)公佈,截至2023年3月31日止年度,公司收益為38.754億港元,同比增長32.7%;純利為1.07億港元,同比減少60.4%;基本每股盈利為5.9港仙,擬派末期息每股4.2港仙。
於2023財年,集團的收入及銷售額創歷史新高,分別達38.754億港元及38.914億港元,同比分別增長32.7%及24.6%。歸功於2023年初香港及中國內地之間恢復跨境旅遊後吸引更多內地遊客迴流,集團於2023財年下半年於各業務板塊(中國內地除外)實現額外的銷售額增長。集團實現24.1%的強勁內部增長,這得益於我們醫療保健生態系統中強勁的內部增長及成功的跨品牌轉診帶來的醫療分部的增長。年內完成的併購交易的收入為1.541億港元,佔總收入的4.0%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.